Table 2.
Biomatrix Alpha versus LEADERS : unadjusted MACE at 2 years.
| CoCr-BP-BES (n = 400) | SS-BP-BES (n = 857) | Hazard ratio | P value | |
|---|---|---|---|---|
| MACE | 26 (6.65%) | 112 (13.23%) | 0.48 [0.31–0.73] | 0.0005 |
| - Cardiac death | 4 (1.01%) | 27 (3.21%) | 0.31 [0.11–0.89] | 0.022 |
| - MI | 12 (3.13%) | 55 (6.48%) | 0.46 [0.24–0.85] | 0.012 |
| - cd-TVR | 16 (4.09%) | 65 (7.8%) | 0.51 [0.3–0.89] | 0.0152 |
| All death | 15 (3.82%) | 40 (4.72%) | 0.79 [0.44–1.44] | 0.449 |
| Target vessel MI | 5 (1.29%) | 27 (3.18%) | 0.39 [0.15–1.03] | 0.048 |
| Definite or probable stent thrombosis | 3 (0.81%) | 26 (3.07%) | 0.25 [0.08–0.82] | 0.013 |
| Any revasc | 29 (7.46%) | 143 (17.14%) | 0.40 [0.27–0.60] | <0.0001 |
| TVF (cardiac death or TV-MI or cd-TVR) | 20 (5.09%) | 96 (11.36%) | 0.43 [0.27–0.7] | 0.0004 |
| POCE (all death or any MI or any revasc) | 43 (10.9%) | 192 (22.58%) | 0.44 [0.32–0.61] | <0.0001 |
revasc = revascularization, cd-TVR = clinically driven target vessel revascularization, CoCr-BP-BES = cobalt-chromium biodegradable polymer Biolimus A9-eluting stent, MACE = major adverse cardiac events, MI = myocardial infarction, POCE = patient-oriented composite endpoint, SS-BP-BES = stainless steel biodegradable polymer Biolimus A9-eluting stent, and TVF = target vessel failure.